Medincell Stock Drops 2.5%, Weekly Decline Reaches 12%

A Decline that Pushes the Stock Below Its Three Moving Averages

Medincell stock loses 2.42% at €25.78 during the session, against a 0.10% rise for the SBF 120. The stock is among the largest declines in the broader index. Today's drop brings the weekly loss to 12%, partially erasing the quarterly gain, now reduced to 2.6%. Over twelve months, the performance remains largely positive, at nearly 59%.

The stock has fallen below its three moving averages, with a gap of 4.4% below the MM20 (€26.97) and 4.9% below the MM50 (€27.10). The MM200, at €26.57, is also below, with the price moving 3% under it. The RSI at 45 remains in a neutral zone, without a marked oversold signal. The technical support identified at €24.08 still offers a margin of 6.6% relative to the current price.

A Fundamental Context Weighing Down Since the Annual Accounts Release

Today's decline extends a sequence that began with the publication of the annual accounts on June 17, which led to a 13.5% drop in the stock. During this announcement (fiscal year 2025/2026), the net loss had widened to €31.3M, from €18.4M a year earlier, despite a 42% increase in Uzedy royalties to €9.3M. The company had then cited among its opportunities the commercial launch of Olanzapine LAI planned for Q4 2026 and among its risks the increase in operating expenses to support expansion.

Based on the earnings per share expected by the consensus of analysts surveyed, the stock is priced at about 30.7 times the earnings for the following year, a multiple that reflects the biotech's profile in the transition phase towards recurring revenues. The next key milestone for the stock remains the commercial launch of Olanzapine LAI expected in the last quarter of 2026.